PUBLIC COMPANY
save$ZURAZura Bio Ltd
$ZURA5.6400-0.88%La Jolla, CA, USupdated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warningThe deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.biopharma_dive · 5d ago
- STAT+: Gene therapy’s long-debated cancer risk materializesFor years, gene therapy researchers debated whether the viruses they use to ferry replacement genes into cells could cause tumors. A small number of cases now offer strong evidence that…stat · 7d ago
- Zura reports Phase 2 flop in painful skin disorder, stock nosedivesA small biotech’s stock collapsed after the company reported a Phase 2 failure in a debilitating skin condition. Zura Bio said Monday morning that both doses of its experimental drug tibulizumab fa…endpoints · 7d ago
- Zura scraps hidradenitis suppurativa program after phase 2 miss, sinking stockZura Bio’s tibulizumab has flunked a phase 2 hidradenitis suppurativa trial, prompting the biotech to end development in the indication while continuing studies in other settings.fiercebiotech · 8d ago
- JATT mastermind launches latest biotech-focused SPAC via $60M IPOJust two months after Someit Sidhu, M.D., succeeded in pairing off his second special purpose acquisition company (SPAC) with Talawar Therapeutics, the biotech entrepreneur is back at it again.fiercebiotech · 2mo ago
Data sources
last refreshed 52m ago
Found something off?
comments(0)
5-min edit window · permanent after that